专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07892762B2 Method for diagnosing irritable bowel syndrome and monitoring inflammatory bowel disease 有权
标题翻译：诊断肠易激综合征和监测炎症性肠病的方法
公开(公告)号：US07892762B2
公开(公告)日：2011-02-22
申请号：US12486727
申请日：2009-06-17
申请人： James Hunter Boone , David Maxwell Lyerly , Tracy Dale Wilkins , Richard Littleton Guerrant
发明人： James Hunter Boone , David Maxwell Lyerly , Tracy Dale Wilkins , Richard Littleton Guerrant
IPC分类号： G01N33/00
CPC分类号： G01N33/6893 , G01N2333/79 , G01N2800/065
摘要： A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.
摘要翻译：一种通过测定临床标本（如粪便，粘液和胆汁）中总内源性人乳铁蛋白水平来帮助区分肠易激综合征与炎症性肠病的方法，其中乳铁蛋白水平升高基本上不排除IBS和其他非炎性病因诊断，并提供可用于这种方法的试剂盒。进一步提供一种定量临床标本中的总内源性人乳铁蛋白水平的方法，例如粪便，粘液和胆汁，以监测具有炎症性肠病的人的胃肠道炎症。

2. 发明申请

US20120276059A1 FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR MONITORING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE 审中-公开
标题翻译： FECAL LACTOFERRIN作为用于确定疾病严重程度的生物标记物和用于监测患有CLOSTRIDIUM DIFFICILE病的患者的感染
公开(公告)号：US20120276059A1
公开(公告)日：2012-11-01
申请号：US13457049
申请日：2012-04-26
申请人： JAMES HUNTER BOONE , DAVID M. LYERLY , TRACY D. WILKINS , ROBERT J. CARMAN
发明人： JAMES HUNTER BOONE , DAVID M. LYERLY , TRACY D. WILKINS , ROBERT J. CARMAN
IPC分类号： G01N33/569 , C12Q1/18 , A61K31/4164 , A61K38/16 , A61K35/74 , G01N33/573 , C12Q1/68
CPC分类号： G01N33/56911 , A61K31/4164 , A61K31/7034 , A61K35/74 , A61K38/14 , A61K45/06 , G01N2333/33 , G01N2333/79 , G01N2800/52 , G01N2800/56
摘要： Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence of C. difficile disease is detected using a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected of C. difficile disease, if GDH is detected indicating the presence of C. difficile, and then toxins A and/or B are detected to indicate toxigenic C. difficile and support a diagnosis of C. difficile-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.
摘要翻译：艰难梭菌病涉及一系列临床表现，从轻度到自限性腹泻到威胁生命的假膜性结肠炎和巨结肠。艰难梭菌的病例根据疾病的严重程度不同地进行治疗。轻度和中度病例可用甲硝唑治疗，而中重度和复发病例通常用万古霉素或fidaxomicin治疗。使用包括艰难梭菌抗原（GDH），毒素A和B以及粪便乳铁蛋白的生物标志物组检测艰难梭菌病的存在。在疑似艰难梭菌病的患者中，如果检测到GDH，表明存在艰难梭菌，然后检测到毒素A和/或B，以表明产毒性艰难梭菌，并支持艰难梭菌相关疾病，粪便通过指示肠道炎症的量来测量乳铁蛋白浓度以确定疾病的严重性。

3. 发明授权

US07192724B2 Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactoferrin as a marker 有权
标题翻译：使用总内源性乳铁蛋白作为标记来区分肠易激综合征与炎症性肠病（IBD）和IBD患者的方法
公开(公告)号：US07192724B2
公开(公告)日：2007-03-20
申请号：US10002842
申请日：2001-11-14
申请人： James Hunter Boone , David Maxwell Lyerly , Tracy Dale Wilkins , Richard Littleton Guerrant
发明人： James Hunter Boone , David Maxwell Lyerly , Tracy Dale Wilkins , Richard Littleton Guerrant
IPC分类号： G01N33/00
CPC分类号： G01N33/6893 , G01N2333/79 , G01N2800/065
摘要： A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.
摘要翻译：一种通过测定临床标本（如粪便，粘液和胆汁）中总内源性人乳铁蛋白水平来帮助区分肠易激综合征与炎症性肠病的方法，其中乳铁蛋白水平升高基本上不排除IBS和其他非炎性病因诊断，并提供可用于这种方法的试剂盒。进一步提供了一种定量临床标本中的总内源性人乳铁蛋白水平的方法，例如粪便，粘液和胆汁，以监测具有炎症性肠病的人的胃肠道炎症。

4. 发明授权

US06872540B2 Method and apparatus for distinguishing Crohn's disease from ulcerative colitis and other gastrointestinal diseases by detecting the presence of fecal antibodies to Saccharomyces cerevisiae 有权
标题翻译：通过检测对酿酒酵母的粪便抗体的存在来区分克罗恩病与溃疡性结肠炎和其他胃肠道疾病的方法和装置
公开(公告)号：US06872540B2
公开(公告)日：2005-03-29
申请号：US10280564
申请日：2002-10-25
申请人： James Hunter Boone , David Maxwell Lyerly , Tracy Dale Wilkins
发明人： James Hunter Boone , David Maxwell Lyerly , Tracy Dale Wilkins
IPC分类号： G01N33/564 , G01N33/569 , G01N33/53
CPC分类号： G01N33/564 , G01N2469/20 , Y10S435/975
摘要： A method and apparatus for the differentiation of Crohn's disease from other gastrointestinal illnesses, such as ulcerative colitis and irritable bowel syndrome, using the presence of fecal anti-Saccharomyces cerevisiae antibodies (ASCA) as a marker for Crohn's disease are provided. The apparatus includes an enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobins for the measurement of total endogenous ASCA in a human fecal sample. The method and apparatus may be used by healthcare providers to distinguish Crohn's disease from other gastrointestinal illnesses, such as ulcerative colitis and irritable bowel syndrome.
摘要翻译：提供了使用粪便抗酿酒酵母抗体（ASCA）作为克罗恩病的标记物来克隆克罗恩病与其他胃肠道疾病如溃疡性结肠炎和肠易激综合征的分化的方法和装置。该装置包括酶联免疫测定或其他免疫测定，其利用人免疫球蛋白特异性抗体测量人粪便样品中的总内源性ASCA。医疗保健提供者可以使用该方法和装置来区分克罗恩病与其他胃肠道疾病如溃疡性结肠炎和肠易激综合征。

5. 发明授权

US07736858B2 Method for distinguishing ulcerative colitis from Crohn's disease by detecting the presence of fecal anit-neutrophil cytoplasmic antibodies (ANCA) 有权
标题翻译：通过检测粪便抗中性粒细胞胞浆抗体（ANCA）的存在来区分溃疡性结肠炎与克罗恩病的方法
公开(公告)号：US07736858B2
公开(公告)日：2010-06-15
申请号：US10656034
申请日：2003-09-05
申请人： James Hunter Boone , David Maxwell Lyerly , Tracy Dale Wilkins
发明人： James Hunter Boone , David Maxwell Lyerly , Tracy Dale Wilkins
IPC分类号： G01N33/53
CPC分类号： C07K16/4283 , G01N33/56972 , G01N33/6854 , G01N33/6893 , G01N2800/06 , G01N2800/065
摘要： A method and apparatus for the differentiation of ulcerative colitis from Crohn's disease and other gastrointestinal illnesses using the presence of anti-neutrophil cytoplasmic antibodies (ANCA) as a marker of ulcerative colitis is described. The apparatus consists of either a qualitative enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobulins for the measurement of total endogenous ANCA in a human sample. The method and apparatus can be used by healthcare providers to distinguish ulcerative colitis from Crohn's disease and other gastrointestinal illnesses.
摘要翻译：描述了使用抗中性粒细胞胞质抗体（ANCA）作为溃疡性结肠炎的标志物来存在克罗恩病和其他胃肠疾病的溃疡性结肠炎分化的方法和装置。该设备由定性酶联免疫测定法或其他免疫测定法组成，其使用人免疫球蛋白特异性抗体来测量人体样品中总内源性ANCA。该方法和装置可被医疗保健提供者用来区分溃疡性结肠炎与克罗恩病和其他胃肠道疾病。

6. 发明申请

US20120276060A1 FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR TREATING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE 审中-公开
标题翻译： FECAL LACTOFERRIN作为用于确定疾病严重程度的生物标记物和用于治疗患有CLOSTRIDIUM DIFFICILE病的患者的感染
公开(公告)号：US20120276060A1
公开(公告)日：2012-11-01
申请号：US13457064
申请日：2012-04-26
申请人： JAMES HUNTER BOONE , DAVID M. LYERLY , TRACY D. WILKINS , ROBERT J. CARMAN
发明人： JAMES HUNTER BOONE , DAVID M. LYERLY , TRACY D. WILKINS , ROBERT J. CARMAN
IPC分类号： G01N33/569 , A61K35/74 , A61K38/16 , A61K31/4164
CPC分类号： G01N33/56911 , A61K31/4164 , A61K31/7034 , A61K35/74 , A61K38/14 , A61K45/06 , G01N2333/33 , G01N2333/79 , G01N2800/52 , G01N2800/56
摘要： Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence of C. difficile disease is detected using a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected of C. difficile disease, if GDH is detected indicating the presence of C. difficile, and then toxins A and/or B are detected to indicate toxigenic C. difficile and support a diagnosis of C. difficile-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.
摘要翻译：艰难梭菌病涉及一系列临床表现，从轻度到自限性腹泻到威胁生命的假膜性结肠炎和巨结肠。艰难梭菌的病例根据疾病的严重程度不同地进行治疗。轻度和中度病例可用甲硝唑治疗，而中重度和复发病例通常用万古霉素或fidaxomicin治疗。使用包括艰难梭菌抗原（GDH），毒素A和B以及粪便乳铁蛋白的生物标志物组检测艰难梭菌病的存在。在疑似艰难梭菌病的患者中，如果检测到GDH，表明存在艰难梭菌，然后检测到毒素A和/或B，以表明产毒性艰难梭菌，并支持艰难梭菌相关疾病，粪便通过指示肠道炎症的量来测量乳铁蛋白浓度以确定疾病的严重性。

7. 发明授权

US07785818B2 Inflammatory bowel disease and irritable bowel syndrome IBD-first chek diagnostic panel 有权
标题翻译：炎性肠病和肠易激综合征IBD-first chek诊断面板
公开(公告)号：US07785818B2
公开(公告)日：2010-08-31
申请号：US10693377
申请日：2003-10-24
申请人： James Hunter Boone , David Maxwell Lyerly , Tracy Dale Wilkins
发明人： James Hunter Boone , David Maxwell Lyerly , Tracy Dale Wilkins
IPC分类号： G01N33/53
CPC分类号： G01N33/56972 , G01N33/6893 , G01N2333/395 , G01N2333/79 , G01N2469/20 , G01N2800/065
摘要： A method for the differentiation of inflammatory bowel disease (IBD) from irritable bowel disease (IBS) followed by distinguishing ulcerative colitis and Crohn's disease from other gastrointestinal illnesses. This highly differential method first uses the presence of elevated lactoferrin as a marker of intestinal inflammation to differentiate IBD from IBS. Patients suspected of IBD are then analyzed for fecal anti-Saccharomyces cerevisiae antibodies (ASCA) as an indicator of Crohn's disease and fecal anti-neutrophil cytoplasmic antibodies (ANCA) as an indicator of ulcerative colitis. IBD patients are further monitored for intestinal inflammation using fecal lactoferrin to evaluate the effectiveness of medical therapy and to predict relapse. The apparatus comprises either a qualitative enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobins for the measurement of total endogenous lactoferrin, ASCA and ANCA in human feces. The method and apparatus can be used by healthcare providers to identify IBD and distinguish ulcerative colitis from Crohn's disease.
摘要翻译：一种从肠易激综合征（IBS）分化炎症性肠病（IBD）的方法，然后区分溃疡性结肠炎和克罗恩病与其他胃肠道疾病。这种高度差异的方法首先使用升高的乳铁蛋白作为肠炎症的标志物来区分IBD与IBS。然后分析疑似IBD的患者粪便抗Saccharomyces cerevisiae抗体（ASCA）作为克罗恩病和粪便抗嗜中性粒细胞胞质抗体（ANCA）的指标，作为溃疡性结肠炎的指标。使用粪便乳铁蛋白进一步监测IBD患者的肠道炎症，以评估药物治疗的有效性并预测复发。该装置包括定性酶联免疫测定或其他免疫测定，其使用对人免疫球蛋白特异性的抗体来测量人粪便中的总内源性乳铁蛋白，ASCA和ANCA。该方法和装置可被医疗保健提供者用来识别IBD并将溃疡性结肠炎与克罗恩病区分开来。

8. 发明申请

US20090253155A1 Method For Diagnosing Irritable Bowel Syndrome and Monitoring Inflammatory Bowel Disease 有权
标题翻译：诊断肠易激综合征和监测炎症性肠病的方法
公开(公告)号：US20090253155A1
公开(公告)日：2009-10-08
申请号：US12486727
申请日：2009-06-17
申请人： JAMES HUNTER BOONE , DAVID MAXWELL LYERLY , TRACY DALE WILKINS , RICHARD LITTLETON GUERRANT
发明人： JAMES HUNTER BOONE , DAVID MAXWELL LYERLY , TRACY DALE WILKINS , RICHARD LITTLETON GUERRANT
IPC分类号： G01N33/48
CPC分类号： G01N33/6893 , G01N2333/79 , G01N2800/065
摘要： A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.
摘要翻译：一种通过测定临床标本（如粪便，粘液和胆汁）中总内源性人乳铁蛋白水平来帮助区分肠易激综合征与炎症性肠病的方法，其中乳铁蛋白水平升高基本上不排除IBS和其他非炎性病因诊断，并提供可用于这种方法的试剂盒。进一步提供了一种定量临床标本中的总内源性人乳铁蛋白水平的方法，例如粪便，粘液和胆汁，以监测具有炎症性肠病的人的胃肠道炎症。

9. 发明授权

US07560240B2 Method for monitoring gastrointestinal inflammation in persons with inflammatory bowel disease(IBD) 有权
标题翻译：炎症性肠病（IBD）患者胃肠道炎症监测方法
公开(公告)号：US07560240B2
公开(公告)日：2009-07-14
申请号：US10629975
申请日：2003-07-30
申请人： James Hunter Boone , David Maxwell Lyerly , Tracy Dale Wilkins , Richard Littleton Guerrant
发明人： James Hunter Boone , David Maxwell Lyerly , Tracy Dale Wilkins , Richard Littleton Guerrant
IPC分类号： G01N33/53 , G01N33/543
CPC分类号： G01N33/6893 , G01N2333/79 , G01N2800/065
摘要： A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.
摘要翻译：一种通过测定临床标本（如粪便，粘液和胆汁）中总内源性人乳铁蛋白水平来帮助区分肠易激综合征与炎症性肠病的方法，其中乳铁蛋白水平升高基本上不排除IBS和其他非炎性病因诊断，并提供可用于这种方法的试剂盒。进一步提供了一种定量临床标本中的总内源性人乳铁蛋白水平的方法，例如粪便，粘液和胆汁，以监测具有炎症性肠病的人的胃肠道炎症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式